Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.11, signifying a -0.97% move from its prior day's close.
3 days ago

KUALA LUMPUR: Recursion announced the United States (US) Food and Drug Administration (FDA) has cleared an investigational new drug (IND)...
6 months ago

Recursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND...
3 days ago

Recursion Pharmaceuticals (RXRX) stock gains as FDA clears a clinical trial for the Nvidia (NVDA)-backed biotech's tumor candidate...
3 days ago

Artificial intelligence (AI) companies are well-positioned to disrupt the biotechnology industry. Typically, biotech companies need to...
13 hours ago

Christopher Gibson, the Chief Executive Officer of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), has sold a total of 40,000 shares of the...
1 day ago

Recursion will release proof-of-concept clinical trial data over the next 12 months; investor interest in seeing if AI can speed drug...
1 month ago

Recursion Pharmaceuticals ( ($RXRX) ) just unveiled an announcement. Recursion Pharmaceuticals, Inc. has announced FDA clearance for the...
3 days ago

Recursion has stumbled through an early test of its tech-enabled drug discovery, reporting a hit on safety but failing to wow on the...
1 month ago

Recursion Pharmaceuticals on Tuesday said results from a mid-stage trial showed its lead experimental drug to be safe, the first readout in a...
1 month ago